Therapeutic immune response induced by electrofusion of dendritic and tumor cells

Cellular Immunology

Volumn 220, Issue 1, 2002, Pages 1-12

  Tanaka, Hiroshi ^a   Shimizu, Keiji ^a   Hayashi, Takashi ^a   Shu, Suyu ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

DC tumor hybrids; Dendritic cells; Electrofusion; Immunotherapy; Tumor immunity

Indexed keywords

BETA GALACTOSIDASE; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 10; INTERLEUKIN 12; TUMOR ANTIGEN;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CELL FUNCTION; DENDRITIC CELL; DRUG EFFECT; DRUG RESPONSE; ELECTROFUSION (CELL); FEMALE; HYBRID CELL; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; INTERFERON PRODUCTION; LUNG METASTASIS; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROCESS MODEL; STIMULATION; T LYMPHOCYTE; TECHNIQUE; TUMOR CELL; VACCINATION;

MURINAE;

EID: 0036877104     PISSN: 00088749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-8749(03)00009-1     Document Type: Article

References (53)

1. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature. 392:1998;245-252.
2. Banchereau J., Brier F., Caux C., Davoust J., Lebecque S., Liu Y.J., Pulendran B., Palucka K. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18:2000;767-811.
3. Steinman R.M., Dhodapkar M. Active immunization against cancer with dendritic cells: the near future. Int. J. Cancer. 94:2001;459-473.
4. Zitvogel L., Mayordomo J.I., Tjandrawan T., DeLeo A.B., Clarke M.R., Lotze M.T., Storkus W.J. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med. 183:1996;87-97.
5. McArthur J.G., Mulligan R.C. Induction of protective anti-tumor immunity by gene-modified dendritic cells. J. Immunother. 21:1998;41-47.
6. Kaplan J.M., Yu Q., Piraino S.T., Pennington S.E., Shankara S., Woodworth L.A., Roberts B.L. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. J. Immunol. 163:1999;699-707.
7. Shimizu K., Thomas E.K., Giedlin M., Mule J.J. Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper proteins. Cancer Res. 61:2001;2618-2624.
8. Ashley D.M., Faiola B., Nair S., Hale L.P., Bigner D.D., Gilboa E. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J. Exp. Med. 186:1997;1177-1182.
9. Mitchell D.A., Nair S.K. RNA-transfected dendritic cells in cancer immunotherapy. J. Clin. Invest. 106:2000;1065-1069.
10. Specht J.M., Wang G., Do M.T., Lam J.S., Royal R.E., Reeves M.E., Rosenberg S.A., Hwu P. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against pulmonary metastases. J. Exp. Med. 186:1997;1213-1221.
11. Schreiber H. Tumor immunology, Fundamental Immunology. 1989;Raven Press, New York.
12. Gong J., Chen D., Kashiwaba M., Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat. Med. 3:1997;558-561.
13. Gong J., Chen D., Kashiwaba M., Li Y., Chen L., Takeuchi H., Qu H., Rowse G.J., Gendler S.J., Kufe D. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc. Natl. Acad. Sci. USA. 95:1998;6279-6283.
14. Lespagnard L., Mettens P., Verheyden A.M., Tasiaux N., Thielemans K., van Meirvenne S., Geldhof A., De Baetselier P., Urbain J., Leo O., Moser M. Dendritic cells fused with mastocytoma cells elicit therapeutic antitumor immunity. Int. J. Cancer. 76:1998;250-258.
15. Akasaki Y., Kikuchi T., Homma S., Abe T., Kufe D., Ohno T. Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model. J. Immunother. 24:2001;106-113.
16. Melcher A., Todryk S., Bateman A., Chong H., Lemoine N.R., Vile R.G. Adoptive transfer of immature dendritic cells with autologous or allogeneic tumor cells generates systemic antitumor immunity. Cancer Res. 59:1999;2802-2805.
17. Candido K., Shimizu K., McLaughlin J.C., Kunkel R., Fuller J.A., Redman B.G., Thomas E.K., Nickoloff B.J., Mule J.J. Local administration of dendritic cells inhibits established breast tumor growth: implications for apoptosis inducing agents. Cancer Res. 61:2001;228-236.
18. Zimmerman U., Vienken J. Electric field-induced cell-to-cell fusion. J. Membr. Biol. 67:1982;165-182.
19. Hui S.W., Stenger D.A. Electrofusion of cells: hybridoma production by electrofusion and polyethylene glycol. Methods in Enzymology. 1993;Academic Press, San Diego, CA.
20. Hayashi T., Tanaka H., Tanaka J., Wang R., Averbook B.J., Cohen P.A., Shu S. Immunogenicity and therapeutic efficacy of dendritic-tumor hybrid cells generated by electrofusion. Clin. Immunol. 104:2002;14-20.
21. Hart I.R. The selection and characterization of an invasive variant of the B16 melanoma. Am. J. Pathol. 97:1979;587-600.
22. low cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes J. Immunol. 160:1998;3444-3452.
23. Maraskovsy E., Brasel K., Teepe M., Roux E.R., Lyman S.D., Shortman K., McKenna H.J. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J. Exp. Med. 184:1996;1953-1962.
24. Zimmerman U., Urnovitz H.B. Principles of electrofusion and electropermeabilization. Methods in Enzymology. 1987;Academic Press, San Diego, CA.
25. Yoshizawa H., Chang A.E., Shu S. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and Il-2. J. Immunol. 147:1991;729-737.
26. + T cell in adoptive immunotherapy and the indirect mechanism of tumor rejection Crit. Rev. Immunol. 20:2000;17-56.
27. Lambert L.A., Gibson G.R., Maloney M., Durell B., Noelle R.J., Barth R.J. Jr. Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity. Cancer Res. 61:2001;641-646.
28. Weinberg A.D., Rivera M., Prell R., Morris A., Ramstad T., Vetto J.T., Urba W.J., Alvord G., Bunce C., Shields J. Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J. Immunol. 164:2000;2160-2169.
29. Wilcox R.A., Flies D.B., Zhu G., Johnson A.J., Tamada K., Chapoval A.I., Strome S.E., Pease L.R., Chen L. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J. Clin. Invest. 109:2002;651-659.
30. + T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses J. Exp. Med. 186:1997;47-55.
31. Kjaergaard J., Tanaka J., Kim J.A., Rothchild K., Weinberg A., Shu S. Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of the tumor growth. Cancer Res. 60:2000;5514-5521.
32. Melero I., Shuford W.W., Newby S.A., Aruffo A., Ledbetter J.A., Hellstrom K.E., Mittler R.S., Chen L. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat. Med. 3:1997;682-685.
33. Rissoan M.C., Soumelis V., Kadowaki N., Grouard G., Briere F., de Waal Malefyt R., Liu Y.J. Reciprocal control of T helper cell and dendritic cell differentiation. Science. 283:1999;1183-1186.
34. Cerwenka A., Morgan T.M., Harmsen A.G., Dutton R.W. Migration kinetics and final destination of type 1 and type 2 CD8 effector cells predict protection against pulmonary virus infection. J. Exp. Med. 189:1999;423-434.
35. Nishimura T., Iwakabe K., Sekimoto M., Ohmi Y., Yahata T., Nakui M., Sato T., Habu S., Tashiro H., Sato S., Ohta A. Distinct role of antigen-specific T helper type1 (Th1) and Th2 cells in tumor eradication in vivo. J. Exp. Med. 190:1999;617-628.
36. + T cell subsets during virus infection. Protective capacity depends on effector cytokine secretion and on migratory capability J. Exp. Med. 191:2000;2159-2170.
37. Hu H.-M., Urba W., Fox B.A. Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to type 1 cytokine profile. J. Immunol. 161:1998;3033-3041.
38. + tumor-reactive T cells Laryngoscope. 110:2000;1648-1654.
39. b -restricted CTL epitope of β-galactosidase: potential use in development of immunization protocols for "self" antigens Methods. 12:1997;117-123.
40. Hofmann G.A. Physical and practical electronic aspects of electro cell fusion and electroporation. Electroporation and Electrofusion in Cell Biology. 1989;Plenum, New York.
41. Sowers A.E. Membrane electrofusion: a paradigm for study of membrane fusion mechanism. Methods in Enzymology. 1993;Academic Press, San Diego, CA.
42. Neil G., Zimmerman U. Electrofusion. Methods in Enzymology. 1993;Academic Press, San Diego, CA.
43. White K.L. Electrofusion of mammalian cells. Methods in Molecular Biology. 1995;The Humana Press, Clifton, NJ.
44. Pierre P., Turley S.J., Gatti E., Hull M., Meltzer J., Mirza A., Inaba K., Steinmann R.M., Mellman I. Developmental regulation of MHC class II transport in mouse dendritic cells. Nature. 388:1997;787-792.
45. Turley S.J., Inaba K., Garrett W.S., Ebersold M., Unternaehrer J., Steinman R.M., Mellman I. Transport of peptide-MHC class II complexes in developing dendritic cells. Science. 288:2000;522-527.
46. Knight B.C., Souberbielle B.E., Rizzardi G.P., Ball S.E., Dalgleish A.G. Allogeneic murine melanoma cell vaccine: a model for the development of human allogeneic cancer vaccine. Melanoma Res. 6:1996;299-306.
47. Linardakis E., Bateman A., Phan V., Ahmed A., Gough M., Olivier K., Kennedy R., Errington F., Harrington K.J., Melcher A., Vile R. Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell-tumor cell fusion. Cancer Res. 62:2002;5495-5504.
48. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adoptive immunity. Annu. Rev. Immunol. 13:1995;251-276.
49. Grohmann U., Bianchi R., Ayroldi E., Belladonna M.L., Surace D., Fioretti M.C., Puccetti P. A tumor-associated and self antigen peptide presented by dendritic cells may induce T cell anergy in vivo, but IL-12 can prevent or revert the anergic state. J. Immunol. 158:1997;3593-3602.
50. De Smedt T., Smith J., Baum P., Fanslow W., Butz E., Maliszewski C. Ox40 costimulation enhances the development of T cell responses induced by dendritic cells in vivo. J. Immunol. 168:2002;661-670.
51. + T cells J. Exp. Med. 185:2002;2133-2141.
52. Josien R., Li H.L., Ingulli E., Sarma S., Wong B.R., Vologodskaia M., Steinman R.M., Choi Y. TRANCE, a tumor necrosis family member, enhances the longevity and adjuvant properties of dendritic cells in vivo. J. Exp. Med. 191:2000;495-502.
53. Koido S., Tanaka Y., Chen D., Kufe D., Gong J. The kinetics of in vivo priming of CD4 and CD8 T cells by dendritic/tumor fusion cells in MUC1-transgenic mice. J. Immunol. 168:2002;2111-2117.